Andrew Green of Gainesville, Georgia, has announced a strategic partnership with SpeciCare to enhance cancer treatment and research through the collection, testing, and preservation of live tumor tissue. SpeciCare, a leader in advanced genomics and personalized cancer care, aims to provide innovative solutions and new treatment opportunities for cancer patients, leveraging Green’s expertise to advance clinical research and improve patient outcomes.
Atlanta, GA – June 18, 2024 – SpeciCare, a leading company in the field of advanced genomics and personalized cancer care, is proud to announce significant advancements in its mission to revolutionize cancer treatment. Andrew Green of Gainesville, Georgia explains that with a focus on innovative solutions for collecting, testing, and preserving live tumor tissue, SpeciCare is at the forefront of providing new treatment opportunities and clinically actionable information for patients battling cancer.
Andrew Green of Gainesville, Georgia, shares that for more than 40 years, Ken Dixon, M.D., FACS, has treated cancer patients in his practice located in Gainesville, GA. “After a lifetime of taking care of cancer patients, telling a patient or a family member ‘there is nothing left to do’ just got harder and harder,” Dixon said. Driven by these very personal experiences with his patients, in 2015, Dixon began a journey to do more. This journey led him to tumor tissue and its power to create new options in care. It also led him to the emerging field of precision medicine and the development of a tissue storage and banking process for the individual benefit of the patient called SpeciCare.
Eighty-five percent of cancers are treated in community settings such as Gainesville. Andrew Green of Gainesville, Georgia shares that Dixon believes SpeciCare can serve as the missing link connecting community-based care to the most advanced medical treatments for the cancer patient and deliver that treatment, for the most part, at home.
In today’s growing revolution of personalized cancer therapies, saving as much available tumor tissue from each patient is now more important than ever. Discarding valuable tumor tissue is no longer an option, and keeping as much of it as possible is needed to derive critical data to drive the best treatment decisions. Andrew Green of Gainesville, Georgia, explains that SpeciCare is uniquely positioning itself to be a central hub to acquire, process, and bank tumors from individual patients to derive critical genetic and functional data guiding not only more individualized therapies but also as a valuable source of tissue for research on more highly effective cancer therapies.
SpeciCare saves an individual’s living tumor tissue by freezing it in a viable (living) state, making it available for individual, patient-directed research and clinical testing. A small amount of dead tumor tissue is currently used by local pathology, discarding the rest as medical waste. SpeciCare’s live tumor tissue banking process enables access to previously inaccessible innovative testing, clinical trials, and cutting-edge therapies to improve patient outcomes and quality of life.
SpeciCare is also excited to announce a strategic partnership with Dr. Andrew Green, a surgical GYN oncologist. Dr. Andrew Green of Gainesville, Georgia, has joined SpeciCare as a scientific advisor, contributing his extensive expertise to shape the company’s strategic direction. He has played a crucial role in building a biorepository of cancer tumor tissue that has been utilized to advance clinical research for new immunotherapies. Additionally, Dr. Andrew Green of Gainesville, Georgia, has contributed significantly to SpeciCare’s clinical research projects, aiding in the development of ex-vivo drug panel testing and advanced molecular pathology analysis to help personalize treatment options for his patients. Through his partnership with SpeciCare, Dr. Green has provided his patients with new options for ex-vivo drug panel testing, enhancing their treatment possibilities and outcomes. Dr. Andrew Green of Gainesville, Georgia, has also contributed more samples than any other surgeon to the latest research project, which examines the accuracy of genomic sequencing tests by comparing the traditional tissue preservation method of FFPE vs. state-of-the-art methods utilizing cryopreservation.
“We know that when time matters most, patients want answers, options, and quality of life,” Dixon said. “By bringing the focus of cancer research to the individual patient, we believe we will be able to provide access to solutions that could extend life beyond months to years. We aren’t doing the science. We are just providing access to it.”
Andrew Green of Gainesville, Georgia shares that Dixon’s message to patients and their families is a simple one: “You only get one chance to save your tumor tissue. Don’t throw it away.”
For more information about SpeciCare, visit specicare.com or call (833) 242- 2873.
About SpeciCare
SpeciCare is an advanced genomics company dedicated to providing innovative solutions for collecting, testing, and preserving live tumor tissue. By offering new treatment opportunities and clinically actionable research information, SpeciCare aims to improve patient outcomes and advance the field of personalized cancer care. The company participates in clinical research trials involving tumor and liquid biopsy collection for ctDNA, MRD, and RNA diagnostic studies for early cancer detection.
Media Contact:
For more information, please contact R. Scott Cooper, Chief Operating Officer & Head of Business Development at SpeciCare, at [email protected] or call 404-849-8203 or visit www.specicare.com.
